{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:27:18Z","timestamp":1793698038725,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University","award":["Summer Vacation Scholarship"],"award-info":[{"award-number":["Summer Vacation Scholarship"]}],"id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Adelaide University","id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Medicine shortages can disrupt glaucoma management and necessitate therapeutic substitution. Understanding how shortages affect access to first-line treatments for glaucoma is important for optometrists when monitoring intraocular pressure control, and pharmacists when counselling patients and coordinating care during periods of limited medicine availability. Timolol, a non-selective beta-blocker, is a first-line treatment for glaucoma and ocular hypertension and has experienced international shortages in recent years. Between August 2024 and May 2025, Australia experienced a nationwide shortage of timolol-containing eye drops, raising concerns regarding continuity of care, access to treatment, and therapeutic substitution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To descriptively examine the impact of the 2024\u20132025 timolol eye drop shortage on dispensing patterns of antiglaucoma medicines in Australia and assess the contribution of imported products in mitigating the shortage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A retrospective drug utilisation study was conducted using publicly available aggregate Pharmaceutical Benefits Scheme (PBS) and Repatriation PBS dispensing data from January 2020 to August 2025. Monthly dispensings of antiglaucoma preparations (ATC S01E) were standardised per 100,000 population and analysed using descriptive time-series methods. Dispensing trends were compared before, during, and after the shortage, with stratification by timolol formulation, therapeutic class, and product type (locally supplied versus overseas imports).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The late 2024 and early 2025 timolol shortage was associated with a sustained decline in dispensing of single-ingredient extended-release timolol, decreasing from approximately 40 dispensings per 100,000 population per month before the shortage to 1.07 by March 2025. Dispensing of standard-release timolol increased temporarily in October 2024 before declining in a similar pattern. Overseas imports accounted for 24.3% of all timolol dispensings during the shortage period and peaked at 87% of timolol dispensings in March 2025. Despite regulatory approval of imported products, overall timolol utilisation remained below pre-shortage levels. Alternative therapeutic classes, including prostaglandin analogues and carbonic anhydrase inhibitors, showed modest increases in dispensing, suggesting potentially limited therapeutic substitution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The timolol shortage disrupted access to a cornerstone first-line treatment for glaucoma. Regulatory intervention through the approval of imported products partially mitigated the shortage but did not restore utilisation to pre-shortage levels in Australia. Future shortage management strategies should prioritise rapid policy activation and closer alignment of imported products with formulations routinely available in Australia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02209-w","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T07:02:58Z","timestamp":1786172578000},"page":"2312-2321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medicine shortages and glaucoma care: a time-series analysis indicating population-level consequences of a national timolol eye drop shortage"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7100-4416","authenticated-orcid":false,"given":"Erin","family":"Fawcett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6128","authenticated-orcid":false,"given":"Lisa Kalisch","family":"Ellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4350-423X","authenticated-orcid":false,"given":"Simi","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4863-5228","authenticated-orcid":false,"given":"Cassandra","family":"Haines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4915-0423","authenticated-orcid":false,"given":"Helen","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-3504","authenticated-orcid":false,"given":"Jack","family":"Janetzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"2","key":"2209_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/ceo.13989","volume":"50","author":"RJ Casson","year":"2022","unstructured":"Casson RJ. Medical therapy for glaucoma: a review. Clin Exp Ophthalmol. 2022;50(2):198\u2013212. https:\/\/doi.org\/10.1111\/ceo.13989.","journal-title":"Clin Exp Ophthalmol"},{"key":"2209_CR2","doi-asserted-by":"publisher","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101(6):130\u201395. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-EGSguideline.003.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"issue":"2","key":"2209_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00061198-200204000-00007","volume":"11","author":"LJ Katz","year":"2002","unstructured":"Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11(2):119\u201326. https:\/\/doi.org\/10.1097\/00061198-200204000-00007.","journal-title":"J Glaucoma"},{"key":"2209_CR4","doi-asserted-by":"publisher","unstructured":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429\u201340. https:\/\/doi.org\/10.1016\/s0002-9394(00)00538-9.","DOI":"10.1016\/s0002-9394(00)00538-9"},{"issue":"5","key":"2209_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215837","volume":"14","author":"JM Phuong","year":"2019","unstructured":"Phuong JM, Penm J, Chaar B, et al. The impacts of medication shortages on patient outcomes: a scoping review. PLoS ONE. 2019;14(5):e0215837. https:\/\/doi.org\/10.1371\/journal.pone.0215837.","journal-title":"PLoS ONE"},{"issue":"2","key":"2209_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/opo.12180","volume":"35","author":"S Shah","year":"2015","unstructured":"Shah S, Theodossiades J, Chapman K, et al. Impact of supply problems of preservative-free glaucoma medications on patients and hospital staff. Ophthalmic Physiol Opt. 2015;35(2):236\u201341. https:\/\/doi.org\/10.1111\/opo.12180.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"7","key":"2209_CR7","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ophtha.2026.02.025","volume":"133","author":"RT Eakins","year":"2026","unstructured":"Eakins RT, Lowrie LN, Stagg BC, et al. Ophthalmic drug shortages in the United States: survey of the university of Utah drug information service drug shortage database. Ophthalmology. 2026;133(7):895\u2013902. https:\/\/doi.org\/10.1016\/j.ophtha.2026.02.025.","journal-title":"Ophthalmology"},{"key":"2209_CR8","unstructured":"Zhu CQ, Tran JA, Desai M. Impact of the dorzolamide\/timolol shortage on patients with moderate to severe open-angle glaucoma. Investig Opthalmol Vis Sci. 2022;63(7)."},{"key":"2209_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.693426","author":"S Shukar","year":"2021","unstructured":"Shukar S, Zahoor F, Hayat K, et al. Drug shortage: causes, impact, and mitigation strategies. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.693426.","journal-title":"Front Pharmacol"},{"key":"2209_CR10","unstructured":"Australian Government Department of Health and Aged Care TGA. Medicine shortage reports database. 2026. https:\/\/apps.tga.gov.au\/prod\/MSI\/search\/. Accessed 29 Jan 2026."},{"key":"2209_CR11","unstructured":"Australian Government Department of Health and Aged Care TGA. Searching the Australian Register of Therapeutic Goods (ARTG). 2021. https:\/\/www.tga.gov.au\/products\/regulations-all-products\/about-australian-register-therapeutic-goods-artg\/searching-australian-register-therapeutic-goods-artg. Accessed 29 Jan 2026."},{"key":"2209_CR12","unstructured":"Australian Government Department of Health Disability and Ageing Therapeutic Goods Administration. Accessing medicines during a shortage. 2021. https:\/\/www.tga.gov.au\/safety\/shortages-and-supply-disruptions\/medicine-shortages\/accessing-medicines-during-shortage. Accessed 30 Jan 2026."},{"key":"2209_CR13","unstructured":"Australian Government Department of Health and Aged Care TGA. Search the Section 19A approvals database. 2026. https:\/\/www.tga.gov.au\/resources\/section-19a-approvals. Accessed 29 Jan 2026."},{"key":"2209_CR14","unstructured":"Australian Government Therapeutics Good Administration. Supplying overseas medicines when Australian medicines are unavailable or in short supply. 2017. https:\/\/www.tga.gov.au\/resources\/guidance\/supplying-overseas-medicines-when-australian-medicines-are-unavailable-or-short-supply. Accessed 30 Jan 2026."},{"key":"2209_CR15","doi-asserted-by":"crossref","unstructured":"Wang T, Nguyen L, Tan I et al. Evaluating the uptake and potential cost savings of a new 60-day dispensing policy for antihypertensive medicines in Australia. J Hypertens. 2025;43(Suppl 1).","DOI":"10.1097\/01.hjh.0001117472.84114.43"},{"key":"2209_CR16","unstructured":"Australian Government Department of Health Disability and Ageing The Pharmaceutical Benefits Scheme. PBS and RPBS Section 85 and Section 100 Date of Supply Data. 2026. https:\/\/www.pbs.gov.au\/info\/statistics\/dos-and-dop\/dos-and-dop. Accessed 22 July 2026."},{"key":"2209_CR17","unstructured":"Australian Government Department of Health Disability and Ageing Pharmaceutical Benefits Scheme. Repatriation Pharmaceutical Benefits. https:\/\/www.pbs.gov.au\/browse\/rpbs\/rpbs-cards. Accessed 22 Jul 2026."},{"key":"2209_CR18","unstructured":"Australian Bureau of Statistics. National, state and territory population. 2025. https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release#data-downloads. Accessed 1 Dec 2025."},{"key":"2209_CR19","unstructured":"Hava C. What can be done about ongoing medicine shortages? In: Australian Pharmacist. 2024. https:\/\/www.australianpharmacist.com.au\/what-can-be-done-about-ongoing-medicine-shortages\/."},{"key":"2209_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70428","author":"J Janetzki","year":"2025","unstructured":"Janetzki J, Ward M, Hall K, et al. Section A in practice: Assessing the provision of overseas-registered medicines to mitigate the impact of medicine shortages in Australi. Br J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/bcp.70428.","journal-title":"Br J Clin Pharmacol"},{"key":"2209_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajo.2023.05.007","volume":"253","author":"YC Wang","year":"2023","unstructured":"Wang YC, Ling XC, Tsai WH, et al. Risks of topical carbonic anhydrase inhibitors in glaucoma patients with chronic kidney disease: a nationwide population-based study. Am J Ophthalmol. 2023;253:49\u201355. https:\/\/doi.org\/10.1016\/j.ajo.2023.05.007.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2209_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/106002808501900201","volume":"19","author":"WP Munroe","year":"1985","unstructured":"Munroe WP, Rindone JP, Kershner RM. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 1985;19(2):85\u20139. https:\/\/doi.org\/10.1177\/106002808501900201.","journal-title":"Drug Intell Clin Pharm"},{"key":"2209_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcto3010002","author":"X Li","year":"2025","unstructured":"Li X, Balas M, Mathew DJ. A review of ocular and systemic side effects in glaucoma pharmacotherapy. J Clin Transl Ophthalmol. 2025. https:\/\/doi.org\/10.3390\/jcto3010002.","journal-title":"J Clin Transl Ophthalmol"},{"key":"2209_CR24","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","volume":"8","author":"L Mellish","year":"2015","unstructured":"Mellish L, Karanges EA, Litchfield MJBJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8:634. https:\/\/doi.org\/10.1186\/s13104-015-1616-8.","journal-title":"BMC Res Notes"},{"key":"2209_CR25","unstructured":"Williams R Ophthalmology\u2019s Dependence on the Fragile Generic Drug Supply Chain. American Academy of Opthalmology. 2024. https:\/\/www.aao.org\/eyenet\/article\/dependence-fragile-generic-drug-supply-chain. Accessed 29 Jan 2026."},{"issue":"6","key":"2209_CR26","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/s0149-2918(98)80112-4","volume":"20","author":"TR Walters","year":"1998","unstructured":"Walters TR, Maloney S, Slater D, et al. Efficacy and tolerability of 0.5% timolol maleate ophthalmic gel-forming solution QD compared with 0.5% levobunolol hydrochloride BID in patients with open-angle glaucoma or ocular hypertension. Clin Ther. 1998;20(6):1170\u20138. https:\/\/doi.org\/10.1016\/s0149-2918(98)80112-4.","journal-title":"Clin Ther"},{"issue":"4","key":"2209_CR27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/08820538.2021.2003824","volume":"37","author":"R Sakata","year":"2022","unstructured":"Sakata R, Chang PY, Sung KR, et al. Prostaglandin-associated periorbitopathy syndrome (PAPS): addressing an unmet clinical need. Semin Ophthalmol. 2022;37(4):447\u201354. https:\/\/doi.org\/10.1080\/08820538.2021.2003824.","journal-title":"Semin Ophthalmol"},{"issue":"5","key":"2209_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.5301\/ejo.5000292","volume":"23","author":"C Nucci","year":"2013","unstructured":"Nucci C, Varesi C, Martucci A, et al. Efficacy of timolol 0.1% gel and a prostaglandin analog in an unfixed combination compared to the corresponding fixed combinations. Eur J Ophthalmol. 2013;23(5):683\u20139. https:\/\/doi.org\/10.5301\/ejo.5000292.","journal-title":"Eur J Ophthalmol"},{"key":"2209_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2018.04.001","volume":"65","author":"LE Fry","year":"2018","unstructured":"Fry LE, Fahy E, Chrysostomou V, et al. The coma in glaucoma: retinal ganglion cell dysfunction and recovery. Prog Retin Eye Res. 2018;65:77\u201392. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.04.001.","journal-title":"Prog Retin Eye Res"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02209-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02209-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:39:11Z","timestamp":1793695151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02209-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2209"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02209-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10031825\/v1","asserted-by":"object"}]},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"14 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HS is a member of the Therapeutic Goods Administration Medicine Shortages Stakeholder Forum (MSSF) and the Therapeutic Goods Administration Palliative Care Medicine Shortage Action Group. JJ, LKE, EF, SS and CH declare they have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project uses publicly available, de-identified PBS aggregate data. As no individual-level data are used, ethics approval was not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}